// App-Quantinova.ai

BSH19‐PO‐034 : BCL‐XL ‐ a biomarker to predict chronic myeloid leukaemia patients at risk of molecular relapse when TKI treatment is discontinued

Researchers

Presenter

  • C. Lucas

Principal Investigators

  • G. Austin

  • A. Holcroft

  • K. Knight

  • S. Varadarjan

  • R. Clark

Medical Centers

  • Depts of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom

  • Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved